Slide 1: Earnings Call Presentation (FY25 and Mar'25 Qtr.)
Earnings Call Presentation (FY 25 and Mar’25 Qtr.) (8/5/25)
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates” or other words of similar meaning. All statements that address expectations or proj
Slide 3: A world we are seeking to create
+ 27°C A world we are seeking MILLION AIR COOLERS to create SOLD WORLDWIDE 3
Slide 4: Table of Content
Table of Content 1 Performance Highlights 2 Financials 3 Outlook 4
Slide 5: Performance Highlights
Thi Performance Highlights
Slide 6: Performance Highlights: Consol. & Standalone
Performance Highlights: Consol. & Standalone Consol. performance: → Annual revenue milestone of > ₹1,500 cr. (₹1,576 cr.) ▪ 36 v/s FY24 → Highest ever March Qtr. revenue ▪ 47% v/s Mar’24 Qtr. → Highest ever Annual and March Qtr. EBITDA and PAT Standalone performance: → Annual revenue milestone o
Slide 7: Performance Highlights: Overseas Subsidiaries
Performance Highlights: Overseas Subsidiaries GSK, China: → Strong financial performance underpinned by – ▪ Robust growth in both domestic and international markets → Repayment of Symphony Loan through internal accruals: ₹13.5 cr. ▪ Current o/s: ₹49.6 cr. → Technology Transfer Agreement with IMPCO M
Slide 8: Exceptional Items: Impairments and Pathways update [1/2]
Exceptional Items: Impairments and Pathways update [1/2] Write back / Reversal of impairments pertaining to GSK, China → Impairment of Symphony’s – ▪ Equity Investment: ₹1.55 cr. (Mar’20 Qtr.) ▪ Loan:₹7.73 cr. (Mar’24 Qtr.) → Total write-back of ₹9.28 cr. in Mar’25 Qtr. due to – ▪ GSK’s strong finan
Slide 9: Exceptional Items: Impairments and Pathways update [2/2]
Exceptional Items: Impairments and Pathways update [2/2] → Pre-Tax / Post-Tax impact: (₹ Cr.) Consol. Standalone Exceptional Items FY25 Mar’25 Qtr. FY25 Mar’25 Qtr. Impairment write-back - - +7.73 / +7.73 +7.73 / +7.73 (Symphony Loan to GSK) Impairment write-back - - +1.55 / +1.55 +1.55 / +1.55 (Equ
Slide 10: Consolidated Financials
Sympheny all N $ ‘Mi “HL” RT SELL
Slide 11: Consol. Financials: FY25 v/s FY24
Consol. Financials: FY25 v/s FY24 ▲/▼ YoY change (₹ Cr.) Margin % (/ YoY change) Revenue from Gross EBITDA Operations Margin 1,576 775 316 v/s 1,156 (▲36%) v/s 555 (▲40%) v/s 173 (▲83%) 49.19% ( 116 bps) 20.05% ( 512 bps) PBT PAT * ( Excl. Exceptional Item ) 326 213 v/s 183 (▲78%) v/s 148 (▲44%)
Slide 12: Consol. Financial Metrics: FY25 v/s FY24
Consol. Financial Metrics: FY25 v/s FY24 (₹ Cr.) Capital Employed in ROCE (%) RONW (%) Core Business ( Monthly Avg. ) ( PBIT / Capital Employed ) ( PAT / Avg. Net Worth ) 248 101% 28% v/s 302 v/s 50% v/s 18% 12
Slide 13: Actual v/s Proforma Consol. Financials: FY25
Actual v/s Proforma* Consol. Financials: FY25 (₹ Cr.) Actual Proforma* Particulars Consol. Consol. Revenue from operations 1,576 1,290 EBITDA 316 305 PAT 213 222 Capital Employed in Core Business ( Monthly Avg. ) 248 33 *Note: Proforma Consol.: ▪ Excludes CT, Australia and IMPCO, Mexico, intended to
Slide 14: Consol. EBITDA Margin Movement: FY25 v/s FY24
Consol. EBITDA Margin Movement: FY25 v/s FY24 1.93% 20.05% 2.50% -0.48% 1.16% 14.94% EBITDA Gross Employee A&P Other Exp. EBITDA (FY24) Margin Benefits (FY25) 14
Slide 15: Consol. Quarterly Financials: Mar'25 v/s Mar'24
Consol. Quarterly Financials: Mar’25 v/s Mar’24 ▲/▼ YoY change (₹ Cr.) Margin % (/ YoY change) Revenue from Gross Operations Margin 488 226 v/s 332 (▲47%) v/s 161 (▲40%) 46.33% ( 212 bps) EBITDA PAT 103 79 v/s 59 (▲77%) v/s 48 (▲63%) 21.22% ( 358 bps) 16.11% ( 165 bps) 15
Slide 16: Consol. EBITDA Margin Movement: Mar'25 v/s Mar'24
Consol. EBITDA Margin Movement: Mar’25 v/s Mar’24 4.34% 21.22% 17.64% 1.96% -0.60% -2.12% EBITDA Gross Employee A&P Other Exp. EBITDA (Mar'24 Qtr.) Margin Benefits (Mar'25 Qtr.) 16
Slide 17: Standalone Financials
India ka No. 1 Saat symph ony! Thinking of Tomorrow Standalone Financials
Slide 18: Standalone Financials: FY25 v/s FY24
Standalone Financials: FY25 v/s FY24 ▲/▼ YoY change (₹ Cr.) Margin % (/ YoY change) Revenue from Gross EBITDA Operations Margin 1,182 588 287 v/s 796 (▲49%) v/s 390 (▲51%) v/s 161 (▲78%) 49.75% ( 73 bps) 24.25% ( 404 bps) PBT PAT * ( Excl. Exceptional Items ) 329 176 v/s 203 (▲62%) v/s 153 (▲15%
Slide 19: Standalone Financial Metrics: FY25 v/s FY24
Standalone Financial Metrics: FY25 v/s FY24 Capital Employed in ROCE (%) Core Business ( Monthly Avg. ) ( PBIT / Capital Employed ) (-32) Infinite v/s 44 v/s 362% RONW (%) Treasury^ ( PAT / Avg. Net Worth ) ( As on 31/3/25 ) 23% 458 v/s 18% v/s 395 ^ Excl. Loans and Investments in Subsidiaries: ₹258
Slide 20: Standalone EBITDA Margin Movement: FY25 v/s FY24
Standalone EBITDA Margin Movement: FY25 v/s FY24 0.84% 24.25% 2.51% -0.04% 0.73% 20.21% EBITDA Gross Employee A&P Other Exp. EBITDA (FY24) Margin Benefits (FY25) 20
Slide 21: Standalone Quarterly Financials: Mar'25 v/s Mar'24
Standalone Quarterly Financials: Mar’25 v/s Mar’24 ▲/▼ YoY change (₹ Cr.) Margin % (/ YoY change) Revenue from Gross EBITDA Operations Margin 368 180 99 v/s 251 (▲47%) v/s 121 (▲48%) v/s 63 (▲56%) 48.79% ( 34 bps) 26.88% ( 159 bps) PBT PAT * ( Excl. Exceptional Items ) 109 44 v/s 69 (▲57%) v/s 4
Slide 22: Standalone EBITDA Margin Movement: Mar'25 v/s Mar'24
Standalone EBITDA Margin Movement: Mar’25 v/s Mar’24 1.14% 1.20% 26.88% 25.29% 0.34% -1.09% EBITDA Gross Employee A&P Other Exp. EBITDA (Mar'24 Qtr.) Margin Benefits (Mar'25 Qtr.) 22
Slide 23: Subsidiaries' Financials
Thinking of Subsidiaries’ Financials
Slide 24: Subsidiaries' Financials: FY25 and Mar'25 Qtr. [1/2]
Subsidiaries’ Financials: FY25 and Mar’25 Qtr. [1/2] (₹ Cr.) GSK, China Symphony, Brazil Particulars FY25 Mar’25 Qtr. FY25 Mar’25 Qtr. Revenue from operations 100 25 39 4 v/s previous year +126% +118% +53% +9% EBITDA 20 6 1 (-2) v/s previous year +337% +492% (-67%) (-₹0.04 cr.) PAT 15 5 (-3)* (-0.5)
Slide 25: Subsidiaries' Financials: FY25 and Mar'25 Qtr. [2/2]
Subsidiaries’ Financials: FY25 and Mar’25 Qtr. [2/2] (₹ Cr.) IMPCO, Mexico CT, Australia Particulars FY25 Mar’25 Qtr. FY25 Mar’25 Qtr. Revenue from operations 216 81 172 49 v/s previous year +22% +56% (-7%) +12% EBITDA 29 12 (-18) (-5) v/s previous year +9% +65% +17% +42% PAT 18 8 (-28) (-6) v/s pre
Slide 26: Outlook
Thinking of Tomorrow Make your choices wiser + & living healthier. Buying a Symphony Air Cooler is equivalent to planting 14 trees’ p Outlook
Slide 27: Outlook
Outlook Indian Summer 2025: → Commenced with encouraging momentum → Mild and erratic weather so far in current quarter → Still 7 - 11 weeks for summer sales Decent penetration across – → Semi-urban and rural markets → Modern Trade channel → Strategic focus on ▪ scaling emerging markets ▪ acceleratin
Slide 28: Glossary
Glossary Gross Margin (%) : % of Revenue from operations A&P Expenses : Advertisement and Sales Promotion Expenses : Earnings Before Interest, Tax, Depreciation and Amortization EBITDA (Excludes Other Income, Exceptional Items and Foreign Exchange Loss incl. MTM) EBITDA Margin (%) : % of Revenue fro
Slide 29: Scan for Financial Results
Scan for Financial Results (FY25 and Q4 FY25)